Soluble ST2 - Analytical considerations

Thomas Mueller, Allan S Jaffe

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Suppression of tumorigenicity 2 (ST2, also known as interleukin [IL]-1 receptor-like-1) is an IL-1 receptor family member with transmembrane (ST2L) and soluble isoforms (sST2). ST2L is a membrane-bound receptor, and IL-33 is the functional ligand for ST2L. sST2, a soluble truncated form of ST2L, is secreted into the circulation and functions as a "decoy" receptor for IL-33, inhibiting IL-33/ST2L signaling. Blood concentrations of sST2 are increased in inflammatory diseases and heart disease and are considered a valuable prognostic marker in both conditions. In multiple clinical trials, sST2 has emerged as a clinically useful prognostic biomarker in patients with cardiac diseases. Interestingly, sST2 even provides prognostic information in low-risk community-based populations. In this review, we will discuss analytical considerations of measuring circulating sST2 including pre-analytical issues, such as in vitro stability of sST2, biological variation of sST2, and postanalytical issues, such as reference ranges and comparisons to diseased cohorts.

Original languageEnglish (US)
Pages (from-to)8B-21B
JournalAmerican Journal of Cardiology
Volume115
Issue number7
DOIs
StatePublished - Apr 2 2015

Fingerprint

Interleukin-1 Receptors
Heart Diseases
Protein Isoforms
Reference Values
Biomarkers
Clinical Trials
Ligands
Membranes
Population
Interleukin-1 Receptor-Like 1 Protein
Interleukin-33
In Vitro Techniques

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Soluble ST2 - Analytical considerations. / Mueller, Thomas; Jaffe, Allan S.

In: American Journal of Cardiology, Vol. 115, No. 7, 02.04.2015, p. 8B-21B.

Research output: Contribution to journalArticle

Mueller, Thomas ; Jaffe, Allan S. / Soluble ST2 - Analytical considerations. In: American Journal of Cardiology. 2015 ; Vol. 115, No. 7. pp. 8B-21B.
@article{5d73ddf6e7fd4fd19a84bc7c2881371c,
title = "Soluble ST2 - Analytical considerations",
abstract = "Suppression of tumorigenicity 2 (ST2, also known as interleukin [IL]-1 receptor-like-1) is an IL-1 receptor family member with transmembrane (ST2L) and soluble isoforms (sST2). ST2L is a membrane-bound receptor, and IL-33 is the functional ligand for ST2L. sST2, a soluble truncated form of ST2L, is secreted into the circulation and functions as a {"}decoy{"} receptor for IL-33, inhibiting IL-33/ST2L signaling. Blood concentrations of sST2 are increased in inflammatory diseases and heart disease and are considered a valuable prognostic marker in both conditions. In multiple clinical trials, sST2 has emerged as a clinically useful prognostic biomarker in patients with cardiac diseases. Interestingly, sST2 even provides prognostic information in low-risk community-based populations. In this review, we will discuss analytical considerations of measuring circulating sST2 including pre-analytical issues, such as in vitro stability of sST2, biological variation of sST2, and postanalytical issues, such as reference ranges and comparisons to diseased cohorts.",
author = "Thomas Mueller and Jaffe, {Allan S}",
year = "2015",
month = "4",
day = "2",
doi = "10.1016/j.amjcard.2015.01.035",
language = "English (US)",
volume = "115",
pages = "8B--21B",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Soluble ST2 - Analytical considerations

AU - Mueller, Thomas

AU - Jaffe, Allan S

PY - 2015/4/2

Y1 - 2015/4/2

N2 - Suppression of tumorigenicity 2 (ST2, also known as interleukin [IL]-1 receptor-like-1) is an IL-1 receptor family member with transmembrane (ST2L) and soluble isoforms (sST2). ST2L is a membrane-bound receptor, and IL-33 is the functional ligand for ST2L. sST2, a soluble truncated form of ST2L, is secreted into the circulation and functions as a "decoy" receptor for IL-33, inhibiting IL-33/ST2L signaling. Blood concentrations of sST2 are increased in inflammatory diseases and heart disease and are considered a valuable prognostic marker in both conditions. In multiple clinical trials, sST2 has emerged as a clinically useful prognostic biomarker in patients with cardiac diseases. Interestingly, sST2 even provides prognostic information in low-risk community-based populations. In this review, we will discuss analytical considerations of measuring circulating sST2 including pre-analytical issues, such as in vitro stability of sST2, biological variation of sST2, and postanalytical issues, such as reference ranges and comparisons to diseased cohorts.

AB - Suppression of tumorigenicity 2 (ST2, also known as interleukin [IL]-1 receptor-like-1) is an IL-1 receptor family member with transmembrane (ST2L) and soluble isoforms (sST2). ST2L is a membrane-bound receptor, and IL-33 is the functional ligand for ST2L. sST2, a soluble truncated form of ST2L, is secreted into the circulation and functions as a "decoy" receptor for IL-33, inhibiting IL-33/ST2L signaling. Blood concentrations of sST2 are increased in inflammatory diseases and heart disease and are considered a valuable prognostic marker in both conditions. In multiple clinical trials, sST2 has emerged as a clinically useful prognostic biomarker in patients with cardiac diseases. Interestingly, sST2 even provides prognostic information in low-risk community-based populations. In this review, we will discuss analytical considerations of measuring circulating sST2 including pre-analytical issues, such as in vitro stability of sST2, biological variation of sST2, and postanalytical issues, such as reference ranges and comparisons to diseased cohorts.

UR - http://www.scopus.com/inward/record.url?scp=84924977569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924977569&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2015.01.035

DO - 10.1016/j.amjcard.2015.01.035

M3 - Article

VL - 115

SP - 8B-21B

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 7

ER -